This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

A Mount Sinai team showed that the same leukemia mutation behaves differently depending on when it arises during development.

Penn Medicine shows how sustained research investment drives innovation, economic growth, and global health breakthroughs.

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...